Bio-Techne (TECH) financial statements
- FY2026 revenue
- $1.2B▼ −0.4%
- FY2026 net income
- $182M▲ +147.8%
- FY2026 diluted EPS
- $1.16▲ +152.2%
- FY2026 free cash flow
- $263M▲ +2.6%
Bio-Techne income statement
| USD millions | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Period ended | 30 Jun 2026 | 30 Jun 2025 | 30 Jun 2024 |
| Revenue | 1,215 | 1,220 | 1,159 |
| Gross profit | 799 | 790 | 770 |
| Operating income | 252 | 102 | 207 |
| Pretax income | 241 | 98 | 186 |
| Net income | 182 | 73 | 168 |
| Diluted earnings per share | 1.16 | 0.46 | 1.05 |
Bio-Techne balance sheet
| USD millions | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Period ended | 30 Jun 2026 | 30 Jun 2025 | 30 Jun 2024 |
| Cash and cash equivalents | 265 | 162 | 152 |
| Total assets | 2,587 | 2,558 | 2,704 |
| Total liabilities (derived) | 479 | 639 | 635 |
| Total equity | 2,108 | 1,919 | 2,069 |
| Long-term debt | 200 | 346 | 319 |
Bio-Techne cash flow statement
| USD millions | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Period ended | 30 Jun 2026 | 30 Jun 2025 | 30 Jun 2024 |
| Operating cash flow | 292 | 288 | 299 |
| Capital expenditure | -29 | -31 | -63 |
| Free cash flow (derived) | 263 | 257 | 236 |
| Dividends paid | -50 | -50 | -50 |
| Share repurchases | -42 | -276 | -80 |
Quarterly highlights
| USD millions | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 |
|---|---|---|---|---|
| Period ended | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 | 30 Sep 2025 |
| Revenue (derived) | 321 | 311 | 296 | 287 |
| Operating income (derived) | 74 | 75 | 54 | 48 |
| Net income | n/a | 51 | 38 | 38 |
| Diluted earnings per share | n/a | 0.32 | 0.24 | 0.24 |
| Operating cash flow (derived) | 95 | 87 | 82 | 28 |
| Total assets | 2,587 | 2,551 | 2,523 | 2,526 |
Bio-Techne major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| Abigail P. Johnson | 8.1% | 12,754,784 | 6 August 2026 |
| FMR LLC | 8.1% | 12,754,784 | 6 August 2026 |
| Vanguard Capital Management | 7.4% | 11,559,571 | 29 April 2026 |
| BlackRock, Inc. | 7.0% | 11,011,556 | 16 July 2025 |
Bio-Techne 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 23 September 2026 | 8-K | Current report | Current report |
| 14 September 2026 | 8-K | Current report | Current report |
| 24 August 2026 | 10-K | Annual report | Annual report |
| 12 August 2026 | 8-K | Current report | Current report |
| 25 June 2026 | 8-K | Current report | CURRENT REPORT |
| 25 June 2026 | 8-K | Current report | CURRENT REPORT |
| 6 May 2026 | 10-Q | Quarterly report | Quarterly report |
| 6 May 2026 | 8-K | Current report | Current report |
Common questions
What was Bio-Techne's revenue in fiscal 2026?
Bio-Techne reported $1.2 billion in revenue for fiscal 2026, the year ended 30 June 2026, down 0.4% from fiscal 2025.
What was Bio-Techne's net income in fiscal 2026?
Bio-Techne reported net income of $182 million for fiscal 2026, the year ended 30 June 2026, up 147.8% from fiscal 2025. Diluted earnings per share were $1.16.
What was Bio-Techne's free cash flow in fiscal 2026?
Bio-Techne had $263 million in free cash flow in fiscal 2026. Operating cash flow was $292 million and capital expenditure was $28.9 million.
What were Bio-Techne's total assets at the end of fiscal 2026?
Bio-Techne reported total assets of $2.6 billion at the end of fiscal 2026, the year ended 30 June 2026.
How much Bio-Techne history does each plan include?
Free covers the last 3 fiscal years of annual figures. Basic covers the last 10 fiscal years, annual and quarterly. Pro covers the full history, with first reported values and as of dates.
Get these figures through the API
5,000 free requests every month. No card needed.